Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07236099 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
A Phase 2 study, sponsored by Beijing InnoCare Pharma Tech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT07236099 is a Phase 2 study that is actively recruiting participants, run by Beijing InnoCare Pharma Tech Co.. The registered enrollment target is 135 participants.
The verdict
NCT07236099, a Phase 2 study, is actively recruiting participants, sponsored by Beijing InnoCare Pharma Tech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Interventions
- DRUG Placebo
- DRUG ICP-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-11-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07236099
The ClinicalTrials.gov registry entry for NCT07236099 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beijing InnoCare Pharma Tech Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07236099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07236099 about?
NCT07236099 is a clinical study titled "Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis". Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
What is the current status of trial NCT07236099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2025-11-27. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07236099?
The interventions under investigation include: Placebo (DRUG), ICP-322 (DRUG).
Who is sponsoring clinical trial NCT07236099?
This trial is sponsored by Beijing InnoCare Pharma Tech Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.